RNAM - Avidity Biosciences Inc

0   0%

Share volume: 0
Last Updated:
Pharmaceutical Products/Pharmaceutical Preparations: 3.19%

PREVIOUS CLOSE
CHG
CHG%
N/A
0.00
0.00%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
41%
Profitability 35%
Dept financing 21%
Liquidity 50%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
N/A
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
-$1.59
52 WEEK RANGE
N/A - N/A
52 WEEK CHANGE
N/A
MARKET CAP 
10.868 B
YIELD 
N/A
SHARES OUTSTANDING 
155.150 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Sarah Boyce
Region: US
Website: aviditybiosciences.com
Employees: 190
IPO year: 2020
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Avidity Biosciences, Inc. engages in the development of oligonucleotide-based therapies. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the. treatment of Duchenne Muscular Dystrophy.

Recent news